302 related articles for article (PubMed ID: 35486263)
21. Targeting cyclin-dependent kinases in gastrointestinal cancer therapy.
Zhang J; Su G; Lin Y; Meng W; Lai JKL; Qiao L; Li X; Xie X
Discov Med; 2019 Jan; 27(146):27-36. PubMed ID: 30721649
[TBL] [Abstract][Full Text] [Related]
22. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer.
Tsihlias J; Kapusta L; Slingerland J
Annu Rev Med; 1999; 50():401-23. PubMed ID: 10073286
[TBL] [Abstract][Full Text] [Related]
23. The Regulation of Cyclins and Cyclin-Dependent Kinases in the Development of Gastric Cancer.
Javed A; Yarmohammadi M; Korkmaz KS; Rubio-Tomás T
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769170
[TBL] [Abstract][Full Text] [Related]
24. Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-beta.
Ravitz MJ; Wenner CE
Adv Cancer Res; 1997; 71():165-207. PubMed ID: 9111866
[TBL] [Abstract][Full Text] [Related]
25. Dual action of cyclin-dependent kinase inhibitors: induction of cell cycle arrest and apoptosis. A comparison of the effects exerted by roscovitine and cisplatin.
Wesierska-Gadek J; Gueorguieva M; Horky M
Pol J Pharmacol; 2003; 55(5):895-902. PubMed ID: 14704484
[TBL] [Abstract][Full Text] [Related]
26. Keratin 19 regulates cell cycle pathway and sensitivity of breast cancer cells to CDK inhibitors.
Sharma P; Alsharif S; Bursch K; Parvathaneni S; Anastasakis DG; Chahine J; Fallatah A; Nicolas K; Sharma S; Hafner M; Kallakury B; Chung BM
Sci Rep; 2019 Oct; 9(1):14650. PubMed ID: 31601969
[TBL] [Abstract][Full Text] [Related]
27. [Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology].
Viallard JF; Lacombe F; Belloc F; Pellegrin JL; Reiffers J
Cancer Radiother; 2001 Apr; 5(2):109-29. PubMed ID: 11355576
[TBL] [Abstract][Full Text] [Related]
28. Targeting Cyclin-Dependent Kinases in Ovarian Cancer.
Zhou Q
Cancer Invest; 2017 Jul; 35(6):367-376. PubMed ID: 28406716
[TBL] [Abstract][Full Text] [Related]
29. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer.
Catzavelos C; Bhattacharya N; Ung YC; Wilson JA; Roncari L; Sandhu C; Shaw P; Yeger H; Morava-Protzner I; Kapusta L; Franssen E; Pritchard KI; Slingerland JM
Nat Med; 1997 Feb; 3(2):227-30. PubMed ID: 9018244
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic targets in cancer treatment: Cell cycle proteins.
Selvaraj C
Adv Protein Chem Struct Biol; 2023; 135():313-342. PubMed ID: 37061336
[TBL] [Abstract][Full Text] [Related]
31. The evolution of cyclin dependent kinase inhibitors in the treatment of cancer.
Jhaveri K; Burris Rd HA; Yap TA; Hamilton E; Rugo HS; Goldman JW; Dann S; Liu F; Wong GY; Krupka H; Shapiro GI
Expert Rev Anticancer Ther; 2021 Oct; 21(10):1105-1124. PubMed ID: 34176404
[No Abstract] [Full Text] [Related]
32. The emerging roles of the CDK/cyclin complexes in antiviral innate immunity.
Zheng C; Tang YD
J Med Virol; 2022 Jun; 94(6):2384-2387. PubMed ID: 34964486
[TBL] [Abstract][Full Text] [Related]
33. The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma.
García-Reyes B; Kretz AL; Ruff JP; von Karstedt S; Hillenbrand A; Knippschild U; Henne-Bruns D; Lemke J
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30340359
[TBL] [Abstract][Full Text] [Related]
34. Why (multi)targeting of cyclin-dependent kinases is a promising therapeutic option for hormone-positive breast cancer and beyond.
Węsierska-Gądek J; Mauritz M
Future Med Chem; 2016 Jan; 8(1):55-72. PubMed ID: 26692095
[TBL] [Abstract][Full Text] [Related]
35. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation.
Watts CK; Brady A; Sarcevic B; deFazio A; Musgrove EA; Sutherland RL
Mol Endocrinol; 1995 Dec; 9(12):1804-13. PubMed ID: 8614416
[TBL] [Abstract][Full Text] [Related]
36. Cell Cycle-Related Clinical Applications.
Khan MGM; Wang Y
Methods Mol Biol; 2022; 2579():35-46. PubMed ID: 36045196
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer.
Balakrishnan A; Vyas A; Deshpande K; Vyas D
World J Gastroenterol; 2016 Feb; 22(7):2159-64. PubMed ID: 26900281
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of TGF-beta-induced cell cycle arrest.
Hocevar BA; Howe PH
Miner Electrolyte Metab; 1998; 24(2-3):131-5. PubMed ID: 9525695
[TBL] [Abstract][Full Text] [Related]
39. Mechanistic insights into avian reovirus p17-modulated suppression of cell cycle CDK-cyclin complexes and enhancement of p53 and cyclin H interaction.
Chiu HC; Huang WR; Liao TL; Chi PI; Nielsen BL; Liu JH; Liu HJ
J Biol Chem; 2018 Aug; 293(32):12542-12562. PubMed ID: 29907572
[TBL] [Abstract][Full Text] [Related]
40. Targeting cyclins and cyclin-dependent kinases in cancer: lessons from mice, hopes for therapeutic applications in human.
Lee YM; Sicinski P
Cell Cycle; 2006 Sep; 5(18):2110-4. PubMed ID: 16969111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
